A Four-Drug Induction Therapy Including Raltegravir for the Treatment of NaÃÂ¯ve HIV-Infected PatientsKatia Falasca1*, Claudio Ucciferri1,2, Marta Di Nicola3, Francesca Vignale1, Delia Racciatti1 and Jacopo Vecchiet1
- Corresponding Author:
- Prof. Katia Falasca
Clinic of Infectious Diseases
Dept. of Medicine and Science of Aging
“G. d’Annunzio” University, School of Medicine
Via dei Vestini, 66013 Chieti, Italy
Tel: +39 0871 357582
Fax: +39 0871 358595
E-mail: [email protected]
Received date: June 20, 2017; Accepted date: June 24, 2017; Published date: June 29, 2017
Citation: Falasca K, Ucciferri C, Nicola MD, Vignale F, Racciatti D, et al. (2017) A Four-Drug Induction Therapy Including Raltegravir for the Treatment of Naïve HIV-Infected Patients. J AIDS Clin Res 8:705. doi:10.4172/2155-6113.1000705
Copyright: © 2017 Falasca K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Despite the recent advances in antiretroviral therapy, human immunodeficiency virus type 1 (HIV-1) remains a global health threat. The aim of this study was evaluated the efficacy of a four-drug induction antiretroviral therapy (ART), including raltegravir (RAL), on the rapidity of suppression of plasma HIV-RNA below detectable concentrations and its impact on immunological recovery. Methods: In this single centre, randomized prospective trial, 32 naïve HIV+ patients at the same clinical stage were enrolled and randomized for baseline viral load: sixteen subjects started ART with four antiretroviral drugs including RAL, while the remaining patients started the same therapy without RAL. Viro-immunological and metabolic parameters, indexes of hepatic and renal functionality were measured at baseline (T0) and after three (T3), six (T6) and twelve months (T12) from therapy introduction. Results: We observed a faster viral drop in the group under RAL-therapy with respect to the other group. At the first month (T1) of therapy, the HIV-RNA was significantly lower in the patients receiving RAL-therapy (p<0.05). Immunological recovery was higher in patients with RAL than in those on other therapy at all detection times, with a significant increase at T3, T6 and T12 (p=0.02). Conclusion: In this study, we found, for the first time, a rapid and significant improvement in CD4+ T cells count in patients with four drug induction therapies. The four-drug regimen was safe, well tolerated and also associated with a rapid decay of plasma HIV-RNA levels.